CL2009001310A1 - Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en lapreparacion del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (div. sol. 2680-04). - Google Patents

Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en lapreparacion del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (div. sol. 2680-04).

Info

Publication number
CL2009001310A1
CL2009001310A1 CL2009001310A CL2009001310A CL2009001310A1 CL 2009001310 A1 CL2009001310 A1 CL 2009001310A1 CL 2009001310 A CL2009001310 A CL 2009001310A CL 2009001310 A CL2009001310 A CL 2009001310A CL 2009001310 A1 CL2009001310 A1 CL 2009001310A1
Authority
CL
Chile
Prior art keywords
pyridin
methanone
compound
cloophenyl
bistrifluoromethylbenzyl
Prior art date
Application number
CL2009001310A
Other languages
English (en)
Inventor
Marie Reutzel-Edens Susan
Scott Coffey David
Wayne Pedersen Steven
Borghese Alfio
Kaye Footman Pamela
Lenyon Shella
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2009001310A1 publication Critical patent/CL2009001310A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en la preparación del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (Div. Sol. 2680-04).
CL2009001310A 2003-10-24 2009-05-29 Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en lapreparacion del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (div. sol. 2680-04). CL2009001310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
CL2009001310A1 true CL2009001310A1 (es) 2009-12-04

Family

ID=34549327

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2009001310A CL2009001310A1 (es) 2003-10-24 2009-05-29 Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en lapreparacion del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (div. sol. 2680-04).
CL2009001311A CL2009001311A1 (es) 2003-10-24 2009-05-29 Procedimiento para preparar {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)metanona a partir de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona y 1-azidometil-3,5-bistrifluorometilbenceno en presencia de una base y un disolvente (div.sol.2680-04).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2009001311A CL2009001311A1 (es) 2003-10-24 2009-05-29 Procedimiento para preparar {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)metanona a partir de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona y 1-azidometil-3,5-bistrifluorometilbenceno en presencia de una base y un disolvente (div.sol.2680-04).

Country Status (28)

Country Link
US (1) US7381826B2 (es)
JP (1) JP4959336B2 (es)
KR (1) KR100848407B1 (es)
CN (1) CN1863791B (es)
AR (1) AR046131A1 (es)
AT (1) ATE462700T1 (es)
AU (1) AU2004285855B8 (es)
BR (1) BRPI0415010B8 (es)
CA (1) CA2542140C (es)
CL (2) CL2009001310A1 (es)
CR (1) CR8353A (es)
DE (1) DE602004026333D1 (es)
DK (1) DK1675846T3 (es)
EA (1) EA008881B1 (es)
EC (1) ECSP066517A (es)
ES (1) ES2340772T3 (es)
HR (1) HRP20100207T1 (es)
IL (1) IL174926A0 (es)
MA (1) MA28329A1 (es)
MY (1) MY157375A (es)
NO (1) NO335090B1 (es)
NZ (2) NZ580480A (es)
PE (1) PE20050481A1 (es)
PT (1) PT1675846E (es)
TW (1) TW200524906A (es)
UA (1) UA82901C2 (es)
WO (1) WO2005042515A1 (es)
ZA (1) ZA200603234B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721069A2 (pt) * 2006-12-20 2014-02-04 Lilly Co Eli Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
MX2017011279A (es) 2015-03-04 2018-01-25 Vanda Pharmaceuticals Inc Metodo de tratamiento con tradipitant.
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
US11549147B2 (en) 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
EP3710000A1 (en) 2017-11-17 2020-09-23 Vanda Pharmaceuticals Inc. Method of treatment of gastrointestinal diseases with tradipitant
EP3801514A1 (en) 2018-06-08 2021-04-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN111918701A (zh) 2018-09-28 2020-11-10 万达制药公司 曲地匹坦在晕动病中的用途
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US20220096449A1 (en) 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
EP4110335A1 (en) 2020-02-25 2023-01-04 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
WO2023034718A1 (en) 2021-08-31 2023-03-09 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ES2267153T3 (es) * 1996-10-07 2007-03-01 MERCK SHARP & DOHME LTD. Antagonistas del receptor nk-1 penetrantes del snc como agentes antidepresivos y/o antiansiedad.
AU6909600A (en) * 1999-08-13 2001-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
JP2003513095A (ja) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド タキキニン受容体アンタゴニストの多形
US20020044971A1 (en) 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
NZ535886A (en) * 2002-04-26 2007-07-27 Lilly Co Eli Triazole derivatives as tachykinin receptor antagonists

Also Published As

Publication number Publication date
CA2542140A1 (en) 2005-05-12
US20070078166A1 (en) 2007-04-05
HRP20100207T1 (hr) 2010-05-31
BRPI0415010B8 (pt) 2021-05-25
BRPI0415010A8 (pt) 2018-05-08
AU2004285855B2 (en) 2010-12-23
JP2007509143A (ja) 2007-04-12
MY157375A (en) 2016-06-15
EA200600829A1 (ru) 2006-08-25
CR8353A (es) 2006-06-06
BRPI0415010A (pt) 2006-11-07
AR046131A1 (es) 2005-11-23
KR100848407B1 (ko) 2008-07-28
NZ580480A (en) 2010-02-26
IL174926A0 (en) 2006-08-20
US7381826B2 (en) 2008-06-03
ZA200603234B (en) 2007-07-25
AU2004285855B8 (en) 2011-04-28
NO335090B1 (no) 2014-09-08
ECSP066517A (es) 2006-10-10
MA28329A1 (fr) 2006-12-01
PT1675846E (pt) 2010-04-20
EA008881B1 (ru) 2007-08-31
JP4959336B2 (ja) 2012-06-20
NZ545917A (en) 2009-11-27
AU2004285855A1 (en) 2005-05-12
TW200524906A (en) 2005-08-01
ATE462700T1 (de) 2010-04-15
CA2542140C (en) 2012-05-29
CN1863791B (zh) 2011-12-07
ES2340772T3 (es) 2010-06-09
NO20062371L (no) 2006-05-24
CN1863791A (zh) 2006-11-15
KR20060061388A (ko) 2006-06-07
WO2005042515A1 (en) 2005-05-12
PE20050481A1 (es) 2005-09-20
BRPI0415010B1 (pt) 2019-07-09
DK1675846T3 (da) 2010-05-31
UA82901C2 (en) 2008-05-26
DE602004026333D1 (de) 2010-05-12
CL2009001311A1 (es) 2009-10-02

Similar Documents

Publication Publication Date Title
CL2009001310A1 (es) Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en lapreparacion del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (div. sol. 2680-04).
RU2425838C2 (ru) Ингибиторы iap
CO6450624A2 (es) Compuestos vinil indazolilo
ECSP034456A (es) Analogos de somatostatina
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
AR047541A1 (es) Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
ITVI20050152A1 (it) Cartuccia per la conservazione e l'erogazione sterile di un composto bifasico, particolarmente per una resina acrilica
AR051965A1 (es) Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida
IL198775A0 (en) Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
NO20075022L (no) (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
CY1112878T1 (el) Νεο αλας βενζοϋλογονανιδινης
AR038638A1 (es) Mezclas fungicidas a base de protioconazol
ITTO20030986A1 (it) Dispositivo per l'erogazione dosata di un agente liquido di lavaggio o risciacquo, per una macchina lavatrice.
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
MA25908A1 (fr) Chlorhydrate de 5-(4(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)thiazolidine-2,4-dione.
HN2005000205A (es) Compuestos terapeuticos
PL1675846T3 (pl) Nowe krystaliczne postacie {2-[1-(3,5-bis-trifluoro-metylobenzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)metanonu
ECSP034528A (es) Sales de sodio de 5-(4-(n-methyl-n-(2-piridil)amino)etoxi)bencil)tiazolidino-2,4-diona
CY1110642T1 (el) Νεες κρυσταλλικες μορφες {2-[1-(3,5-δις-τριφθορομεθυλ-βενζυλ)-5-πυριδιν-4-υλ-1η-[1,2,3]τριαζολ-4-υλ]- πυριδιν-3-υλ}-(2-χλωροφαινυλ)-μεθανονης
CY1115270T1 (el) Νεο ενδιαμεσο και διεργασια χρησιμα στην παρασκευη {2-[1-(3,5-δις-τριφθορομεθυλ-βενζυλ)-5-πυριδιν-4-υλ-1η-[1,2,3]τριαζολ-4-υλ]-πυριδιν-3-υλ}-(2-χλωροφαινυλ)-μεθανονης
CY1106397T1 (el) Βενζολοσουλφονικη 5-(4-(2-(ν-μεθυλο-ν-(2-πυριδιλ)αμινο)αιθοξυ)βενζυλο) θειαζολιδινο-2,4-διονη ˙ διepγασια παρασκευης αυτης ˙ πολυμορφες ι,ιι και ιιι αυτης ˙ και χρηση αυτης ως φαρμακευτικο δραστικο συστατικο
AR107852A2 (es) Derivados de pirrol como inhibidor de secreción ácida
UY27879A1 (es) Composicion farmaceutica que comprende (s)-(+)-3-(1-(-2-(1-acetil-2,3-dihidro-1h-indol-3-il)etil)-1,2,3,6-tetrahidropiridin-4-ii)-6-cloro-1h-indol
ITBA20030010A1 (it) Pedana elettro-idraulica per piani di carico, avente una
ITPR20040048A1 (it) Collettore di distribuzione di un fluido in una macchina sciacquatrice, sterilizzatrice o soffiatrice.